Organogenesis Holdings Inc. - 8-K Filing
Organogenesis Holdings Inc. reported first-quarter 2026 net revenue of $36.3 million, a 58% decrease from $86.7 million in the same period in 2025, driven by a 63% drop in Advanced Wound Care revenue. The company recorded a net loss of $53.2 million, or $0.44 per share, compared to a $18.8 million, or $0.17 per share, loss in Q1 2025. It revised its 2026 revenue guidance to a range of $270.0 million to $310.0 million, reflecting a 45% to 52% decline from 2025's $564.2 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ORGO